Asvasiran sodium

N/A

Report date: 2023/02/12 00:15:44
NME

Base Information

Drug NameAsvasiran sodium
Drug Alias NameIntranasal ALN-RSV01 - AlnylamAerosolised ALN-RSV01 - AlnylamasvasiranALN-RSV01
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceNucleocapsid proteins modulators
TargetsNucleocapsid proteins
Therapy Area/IndicationsRespiratory Syncytial Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[6] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlnylam Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsRespiratory Syncytial Virus Infections

Other Information

ATC CodeN/A
Related LinksDrugBank